Curious about the latest advances in early-stage breast cancer research and treatment? Join us for a special program featuring Dr. Evelyn Taiwo, a breast medical oncologist at NewYork-Presbyterian Brooklyn Methodist Hospital and an associate professor of clinical medicine at Weill Cornell Medicine. Dr. Taiwo will share key takeaways from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including promising updates that may shape future care.
Key Takeaways From Webinar:
- There is a role for deescalated neoadjuvant chemotherapy regimen in patient with early stage Her2 positive breast cancer.
- Discuss the possibility of omitting carboplatin.
- Elinzanetant is an FDA approved medication to reduce the common side effects of Vasomotor symptoms (hot flashes)
- In women with a previous history of breast cancer, use of local estrogen vaginal estrogen to reduce genitourinary symptoms associated with antiestrogen therapy does increase the risk of breast cancer recurrence.
- Discuss use if conservative measures aren’t effective (non hormonal moisturizers)
- Post menopausal women with small tumors, low grade, HR+, and no suspicious LN on ultrasound may be able to avoid SLNBx